InCephalo’s Post

New strategy for targeting the m6A-writer protein METTL3! Check out our recent publication on the development of METTL3 PROTAC 💊🦠🛑

I learned from one of my previous managers (Andy Barlow) that it’s not important how many things you start, but how many things you finish. Now, after years, with the support of our leaders Priv.- Doz. Dr. med. Lukas Martin, MHBA and Georg Griesemann and the team Adrian Alexandru Chiper, Paula Filip, Balan Andrei Mihai, Adrian Manigutiu, Olguta Stanescu, Adrian Mosutiu, Catalin Bobolicu, we focus on getting the things done while looking into the future 😁. Thanks ABC Incubator for hosting us! Clinomic România II Clinomic

Check out this blog post in Nature Research Communications, written by Isabelle (Qiyuan) Hu, summarizing our team's work on developing an MSI predictor from histopathology images of prostate cancer! 👏

An Update from Catailyst's #Radiopharma Activity Tracker: Marketing Authorization Isotopia Molecular Imaging ltd #Isoprotrace®received marketing authorization in the Netherlands A single sterile vacuum - vial kit, intended for preparing multi-patient doses of Gallium (68Ga) Gozetotide (PSMA -11) within only 5 minutes, saving precious decay time in comparison to a standard synthesis.  https://lnkd.in/eWhuWnqd New Clinical Trials: Phase Ia/b Study Targeted Radionuclide Therapy in Metastatic Prostate Cancer  Castration-resistant Prostate Cancer https://lnkd.in/e758jW7N #ProstateCancer New Clinical Trials: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer  https://lnkd.in/eyQFSrHy New Clinical Trials: Actinium Pharmaceuticals, Inc. Iomab-ACT Targeted Radiotherapy as a conditioning therapy prior to CAR_T cell therapy; replace chemotherapy!! https://lnkd.in/e_tjpSwH Completion of Clinical Trial Nanobiotix, #NBTXR3: a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles  #Cancer, non-small cell lung cancer, #lungcancer #nsclc

Catailyst, Inc. Trending Topics UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UroGen Pharma successfully completed the New Drug Application (NDA) submission for investigational drug UGN-102 (mitomycin) for intravesical solution. This marks a significant advancement in addressing the urgent need for innovative treatments for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGen is optimistic about potential FDA approval in early 2025, pending acceptance for filing and the granting of priority review. https://lnkd.in/eRbThV6F #Biotech #CancerResearch #FDAApproval

Slightly obsessed with this paper by Gu et al that maps the immune composition of the human small intestine from gestation through age 70. We know that the incidence of #colorectalcancer is noticeably increasing in younger people globally (https://lnkd.in/er2aXgkS? American Society of Clinical Oncology (ASCO)). The rationale for this increase in a particular age range is not well understood, although there are a number of hypotheses including environmental factors, microbiome, etc. This paper shows an interesting analysis of #immune #cell populations over the course of a human lifetime, illustrated in Fig1F & 1G. In reviewing this data, one could start to envision a guided therapeutic regimen for #cancer and/or #inflammatory and #autoimmune diseases that shifts based on immune cell milieu over a lifetime. #medicineofthefuture I've known and admired Dr. Liza Konnikova since high school. Tremendous respect for her intellectual contributions and the compassion she brings to her field.

A CRISPR Workflow to Increase Efficacy of CAR-T Engineering and Screening Potent synthetic single guide RNAs (sgRNAs) are critical for functional gene characterization in primary cell models. This is because primary cells are more sensitive and resistant to CRISPR genome engineering than immortalized cancer cell lines. Tune in to our upcoming webinar (March 26, 11 a.m. ET) to gain insight in engineering CD8+ chimeric antigen receptor (CAR) T cells. Register here. https://lnkd.in/gFSkF229 #revvity #biolegend #crispr

DHCRC supports multiple projects in collaboration with Peter MacCallum Cancer Centre (Peter Mac) and we are proud of our partnership with Peter Mac in the fight against cancer.   ✨A medication adherence platform for reducing the cost of medication errors and non-adherence: The SAMSON app is designed to reduce incidents of medication errors and non-adherence by patients, supporting long-term management and adherence of medications.   ✨ CLOTS – technical solution: 4-model decision support tool for all surgical and interventional procedures: This project prevents the prevalence of thromboembolism (TE; clots) with a decision-support model that is personalised to practice.    ✨ A virtual clinical champion empowering optimal, equitable care for individuals living with genetic disorders: This project will develop and pilot a scalable, multidimensional platform (GenCare) to give individuals with genetic disorders access to specialist clinical genetics services.   ✨Implementation of a scalable platform to enable regulated digital health product development and commercialisation: This project enables data aggregation from various Peter Mac data ecosystems, presenting de-identified, curated, and multi-modal datasets for research and development of data.   #WorldCancerDay #Partnership #TogetherAgainstCancer #WorldCancerDay

ONE partner to address your Precision Medicine Oncology needs. Check out our posters and abstracts and schedule a meeting here or message me via DM if you'd like to meet. #Biomarkers #PrecisionMedicine #CDx #ctDNA #LiquidBiopsy #GenomicProfiling #ImmuneProfiling #ClinicalDevelopment #Commercialization